Liver Cancer
634
104
134
281
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
85 trials with published results (13%)
Research Maturity
281 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.8%
56 terminated out of 634 trials
83.4%
-3.1% vs benchmark
9%
56 trials in Phase 3/4
30%
85 of 281 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 281 completed trials
Clinical Trials (634)
Collection of Blood From Patients With Cancer
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
DESTINY-PANTUMOUR04
Large Language Models Assist in Tumor MDT
Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer
Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma
Cancer Loyalty Card Study 2 (CLOCS-2)
Early Detection of Liver Cancer by QUS
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
Pressure-enabled Delivery in Radioembolization (TriNav Study)
Feasibility Study of CBCT for IGRT in Cancer Patients
FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.
TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial